Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘European Cancer Conference 2015’

Dr Jerome GalonDr Jérôme Galon is a leading Immunologist and Research Director at INSERM in Paris.

At the recent European Cancer Congress in Vienna he gave an engaging presentation in the scientific symposium on Cellular Immunotherapy of Cancer.

Afterwards, Dr Galon (pictured right) kindly spoke to BSB about:

  • What is immunosurveillance?
  • How the type, location and density of immune cells present within tumors predicts clinical outcome.
  • The potential of the Immunoscore assay to classify cancers based on their immune profile
  • What the future may hold in terms of personalized cancer immunotherapy.

One only has look at the impressive list of companies for which Dr Galon is a consultant or scientific adviser to see how valued his work in the cancer immunotherapy field is; it was a privilege to talk with him. The excerpts of the in-depth interview he kindly gave make for a good weekend read!

Grab a coffee & bagel and enjoy!

Subscribers can login to read more or you can purchase access below.

For some time now there has been much debate about finding a predictive biomarker of response for EGFR monoclonal antibodies used in the treatment of advanced colorectal cancer.  These include cetuximab (Erbitux) and panitumumab (Vectibix).

After all, we know that they tend to work in wild type disease (as shown in the US label below) and that KRAS and NRAS mutations on codon 12 and 13 on exon 2, as well as others on exon 3 and 4 tend to portend resistance to therapy, but beyond that not much is known.

Cetuximab v2

At the European Cancer Conference in Vienna last month I was intrigued to see some new data emerge that may help researchers better understand and predict which people with metastatic colon cancer are more likely to respond in the future.

Subscribers can log in to learn more or you can sign up in the box below.

error: Content is protected !!